Soltis Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Soltis Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$544K	Buy	1,094 +135	+14%	+$59.8K	0.03%	343
2026 Q1	$428K	Buy	959 +85	+10%	+$39.6K	0.03%	373
2025 Q4	$396K	Buy	874 +116	+15%	+$50K	0.03%	360
2025 Q3	$297K	Sell	758 -38	-5%	-$15.9K	0.02%	378
2025 Q2	$354K	Sell	796 -89	-10%	-$41K	0.03%	293
2025 Q1	$429K	Buy	885 +123	+16%	+$57.3K	0.04%	254
2024 Q4	$307K	Sell	762 -16	-2%	-$7.42K	0.03%	285
2024 Q3	$362K	Buy	778 +83	+12%	+$39.9K	0.04%	258
2024 Q2	$326K	Buy	+695	New	+$302K	0.03%	254
2022 Q3	–	Sell	-7,188	Closed	-$2.02M	–	252
2022 Q2	$2.02M	Buy	7,188 +441	+7%	+$118K	0.29%	84
2022 Q1	$1.76M	Buy	+6,747	New	+$1.6M	0.24%	97

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Soltis Investment Advisors's VRTX Position: Q2 2026 in Review

Soltis Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, buying an estimated $59.8K and bringing the position to 1,094 shares worth $544K. The position accounts for 0.03% of the portfolio, ranked #343.

Soltis Investment Advisors first reported a position in VRTX in Q1 2022 and has held it in 11 quarters since. The position peaked at $2.02M in Q2 2022. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Soltis Investment Advisors held 1,094 shares of Vertex Pharmaceuticals worth $544K as of Q2 2026.
Soltis Investment Advisors bought 135 Vertex Pharmaceuticals shares in Q2 2026, an estimated $59.8K.
Vertex Pharmaceuticals made up 0.03% of Soltis Investment Advisors's portfolio in Q2 2026, its #343 holding.
Soltis Investment Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
Soltis Investment Advisors's Vertex Pharmaceuticals position peaked at $2.02M in Q2 2022.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Soltis Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.